Trial Profile

A clinical trial of KIN-8741 in non-small cell lung cancer and other advanced adult solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KIN-8741 (Primary)
Indications Non-small cell lung cancer; Solid tumours
Focus Adverse reactions
Sponsors Kinnate Biopharma

Most Recent Events

18 Sep 2023 According to a Kinnate Biopharma Inc. media release, the company expects to file IND with the U.S. Food and Drug Administration (FDA) in fourth quarter of 2023.
24 Apr 2023 New trial record
17 Apr 2023 According to a Kinnate Biopharma Inc. media release, company expects to enter the clinic with KIN-8741 in the first half of 2024, pending FDA clearance on its IND application.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com